Development and Evaluation of Buccoadhesive Controlled Release Tablets of Lercanidipine

• Published in: AAPS PharmSciTech Vol. 9; no. 1; pp. 182 - 190
• Main Authors: Charde, Shrikant, Mudgal, Madri, Kumar, Lajwinder, Saha, Ranendra
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.03.2008
• Subjects: Adhesiveness; Administration, Buccal; Animals; Biochemistry; Biomedical and Life Sciences; Biomedicine; Biotechnology; Cheek; Delayed-Action Preparations - administration & dosage; Delayed-Action Preparations - chemistry; Diffusion; Dihydropyridines - administration & dosage; Dihydropyridines - chemistry; Drug Compounding - methods; Drug Evaluation, Preclinical; In Vitro Techniques; Materials Testing; Pharmacology/Toxicology; Pharmacy; Research Article; Swine; Tissue Adhesives - chemistry; hydroxypropyl methylcellulose; mucoadhesive; buccal; poly ethylene oxide; lercanidipine
• ISSN: 1530-9932; 1530-9932
• DOI: 10.1208/s12249-007-9031-7

The purpose of this research was to develop and evaluate buccal mucoadhesive controlled release tablets of lercanidipine hydrochloride using polyethylene oxide and different viscosity grades of hydroxypropyl methylcellulose individually and in combination. Effect of polymer type, proportion and combination was studied on the drug release rate, release mechanism and mucoadhesive strength of the prepared formulations. Buccal mucoadhesive tablets were made by direct compression and were characterized for content uniformity, weight variation, friability, surface pH, thickness and mechanism of release. In order to estimate the relative enhancement in bioavailability one optimized formulation was evaluated in rabbits. Further, placebo tablets were also evaluated for acceptability in human subjects. Results indicated acceptable physical characteristics of designed tablets with good content uniformity and minimum weight variation. Drug release and mucoadhesive strength were found to depend upon polymer type, proportion and viscosity. The formulations prepared using poly ethylene oxide gave maximum mucoadhesion. The release mechanism of most formulations was found to be of anomalous non-Fickian type. In vivo studies of selected formulation in rabbits demonstrated significant enhancement in bioavailability of lercanidipine hydrochloride relative to orally administered drug. Moreover, in human acceptability studies of placebo formulations, the designed tablets adhered well to the buccal mucosa for more than 4 h without causing any discomfort. It may be concluded that the designed buccoadhesive controlled release tablets have the potential to overcome the disadvantage of poor and erratic oral bioavailability associated with the presently marketed formulations of lercanidipine hydrochloride.